Nurix Therapeutics Reports $45.3 Million Q1 2026 Net Loss and $12.4 Million Revenue Boost from Collaboration Agreements

Nurix Therapeutics has released its financial results for the first quarter of 2026 and provided updates on its corporate activities. The company reported a net loss of $45.3 million for the quarter, compared to a net loss of $38.7 million during the same period in 2025. Total revenue for the first quarter reached $12.4 million, reflecting an increase from $10.8 million in the prior year’s corresponding quarter.

The company attributed the rise in revenue primarily to collaboration agreements with pharmaceutical partners, which contributed milestone payments and research funding. Research and development expenses increased to $48.2 million, up from $42.5 million in Q1 2025, driven by expanded clinical trial activities and preclinical research efforts across its pipeline programs. General and administrative expenses also rose slightly to $9.5 million from $8.7 million in the previous year’s first quarter, reflecting higher personnel-related costs and operational growth.

Nurix highlighted progress in its drug discovery platform focused on targeted protein modulation, noting advancements in multiple clinical-stage programs aimed at treating cancer and immune disorders. The company stated that it remains well-capitalized with cash, cash equivalents, and marketable securities totaling approximately $320 million as of March 31, 2026, providing sufficient runway to support ongoing operations into mid-2027.

Additionally, Nurix announced plans to present data from several of its clinical trials at upcoming scientific conferences later this year while continuing discussions with regulatory authorities regarding potential next steps for key programs under development.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 8, 2026

Author

GOAI